undamentalytics Newsletter
Sign in

Journey Medical Corp income statement

In fiscal 2025, Journey Medical Corp reported revenue of $61.9m, up 10.2% on the year before, operating income of −$8.2m (a -13.2% margin) and net income of −$11.4m, or −$0.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue45637479566268
Cost of revenue153231232121—
Gross profit303143563541—
Research and development—3118100—
Selling, general and administrative22405944404443
Operating income8−35−28−2−14−8−3
Interest expense1722344
Income before tax7−42−30−4−15−11−6
Income tax220000—
Net income5−44−30−4−15−11−6
Diluted EPS$0.49−$4.32−$1.69−$0.21−$0.72−$0.47−$0.23
Diluted shares (average)11m10m18m18m20m24m27m
EBITDA8−35—————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DERM vs RMTIAYTU vs DERMAQST vs DERM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Journey Medical Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Journey Medical Corp.